Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates, leading to a 10.44% drop in the price of Telix's American Depositary Shares on July 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has been recognized for its significant settlements, including over $438 million recovered for investors in 2019 and being ranked among the top firms for securities class action settlements since 2013 [4].